Problems at Hospira’s Rocky Mount Plant Costly But ‘Fixable,’ CEO Says

Remediation efforts to right manufacturing woes at Hospira’s Rocky Mount, N.C., facility and other palnts are expected to cost between $300 and $375 million through 2013, but enough progress has been made at Rocky Mount to presume a return to production within weeks, Hospira CEO Michael Ball says.
Drug Industry Daily